Do pharmaceutical sales respond to scientific evidence?

Journal of Economics and Management Strategy

Volumn 11, Issue 4, 2002, Pages 551-594

  Azoulay, Pierre ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0036026762     PISSN: 10586407     EISSN: None     Source Type: Journal    
DOI: 10.1162/105864002320757262     Document Type: Article

References (45)

1. Adams, J. and Z. Griliches, 1996, "Measuring Science: an Exploration," Proceedings of the National Academy of Science, 93, 12664-12670.
2. Arrow, K.J., 1962, "Economic Welfare and the Allocation of Resources for Invention," in R. Nelson, ed., The Rate and Direction of Inventive Activity, Princeton, NJ: Princeton University Press, 609-626.
3. _ 1963, "Uncertainty and the Welfare Economics of Medical Care," American Economic Review, 53, 941-973.
4. Athey, S. and A. Schmutzler, 2001, "Investment and Market Dominance," RAND Journal of Economics, 32, 1-26.
5. Avorn, J., M. Chen, and R. Hartley, 1982, "Scientific versus Commercial Sources of Influence on the Prescribing Behavior of Physicians," American Journal of Medicine, 73, 4-8.
6. Azoulay, P., 2001, "Do Pharmaceutical Sales Respond to Scientific Evidence? Evidence from Anti-Ulcer Drugs," Working Paper, Columbia University.
7. Berndt, E.R., L.T. Bui, D.H. Lucking-Reiley, and G.L. Urban, 1997, "The Roles of Marketing, Product Quality, and Price Competition in the Growth and Composition of the U.S. Antiulcer Drug Industry," in T.F. Bresnahan and R.J. Gordon, eds., The Economics of New Goods, NBER Studies in Income and Wealth, 58, Chicago: University of Chicago Press, 277-322.
8. _, R.S. Pindyck, and P. Azoulay, 2000, "Consumption Externalities and Diffusion in Pharmaceutical Markets: Anti-Ulcer Drugs," NBER Working Paper No. 7772.
9. _, A. Bhattacharjya, D.N. Mishol, A. Arcelus, and T. Lasky, 2001, "Variety, Order of Entry, and Marketing Efforts: An Analysis of the Diffusion of New Antidepressant Medications," Working Paper, MIT.
10. Bero, L. and D. Rennie, 1996, "Influences on the Quality of Published Drug Studies," International Journal of Technology Assessment in Health Care, 12, 209-237.
11. Berry, S.T., 1994, "Estimating Descrete-Choice Models of Product Differentiation," RAND Journal of Economics, 25, 242-262.
12. Bond, R.S. and D.F. Lean, 1977, "Sales, Promotion, and Product Differentiation in Two Prescription Drug Markets," Staff Report to the FTC, Federal Trade Commisison, Washington, DC.
13. Carr, G., 1998, "Trials and Tribulations," The Economist, February 21, S13-S15.
14. Cockburn, I.M. and A.H. Anis, 2001, "Hedonic Analysis of Arthritis Drugs," in D.M. Cutler and E.R. Berndt, eds., Medical Care Output and Productivity, NBER Studies in Income and Wealth, 62, Chicago: University of Chicago Press, 439-458.
15. Coleman, J.S., E. Katz, and H. Menzel, 1966, Medical Innovation: A Diffusion Study, New York: Bobbs-Merrill.
16. Comanor, W.S., 1986, "The Political Economy of the Pharmaceutical Industry," Journal of Economic Literature, 24, 1178-1217.
17. Coscelli, A., 2000, "The Importance of Doctors' and Patients' Preferences in the Prescription Decision," Journal of Industrial Economics, 48, 349-369.
18. Ellison, S.F., I. Cockburn, Z. Griliches, and J. Hausman, 1997, "Characteristics of Demand for Pharmaceutical Products: An Examination of Four Cephalosporins," RAND Journal of Economics, 28, 426-446.
19. Garfield, E., 1986, "Which Medical Journals Have the Greatest Impact?" Annals of Internal Medicine, 105, 313-320.
20. Griliches, Z. and F. Lichtenberg, 1984, "R & D and Productivity Growth at the Industry Level: Is There Still a Relationship?," in Z. Grillches, ed., R & D, Patents, and Productivity. Chicago: University of Chicago Press, 465-502.
21. Hurvitz, M.A. and R.E. Caves, 1988, "Persuasion or Information? Promotion and the Shares of Brand Name and Generic Pharamaceuticals," Journal of Law and Economics, 31, 299-320.
22. Institute for Scientific Information, 1991, Journal Citation Reports, Philadelphia: ISI.
23. Ippolito, P.M. and A.D. Mathios, 1990, "Information, Advertising and Health Choices: A Study of the Cereal Market," RAND Journal of Economics, 21, 459-480.
24. Jorde, R., P.G. Burhol, and T. Hansen, 1987. "Ranitidine 150 mg at night in the prevention of gastric ulcer relapse," Gut, 28(4), 460-463.
25. Kessler, D.A. and W.L. Pines, 1990, "The Federal Regulation of Prescription Drug Advertising and Promotion," JAMA, 264, 2409-2415.
26. King, C., 2000, "Marketing, Product Differentiation, and Competition in the Market for Antiulcer Drugs," Harvard Business School Working Paper 01-014.
27. Leffler, K.B., 1981, "Persuasion or Information? The Economics of Prescription Drugs Advertising," Journal of Law and Economics, 24, 45-74.
28. Manning, P.R. and T.A. Denson, 1980, "How Internists Learned about Cimetidine,' Annals of Internal Medicine, 92, 690-692.
29. McFadden, D., 1984, "Econometric Analysis of Qualitative Response Models," in Z. Griliches and M.D. Intriligator, eds., Handbook of Econometrics, 2, New York: North-Holland, 1396-1457.
30. Milgrom, P. and J. Roberts, 1986, "Price and Advertising Signals of Product Quality," Journal of Political Economy, 94, 796-821.
31. Nelson, P., 1974, "Advertising as Information," Journal of Political Economy, 81, 729-754.
32. Peltzman, S., 1975, "The Diffusion of Pharmaceutical Innovation," in R.B. Helms, ed., Drug Development and Marketing, Washington: AEI Center for Health Policy Research.
33. Ronnen, U., 1991, "Minimum Quality Standards, Fixed Costs, and Competition," RAND Journal of Economics, 22, 490-504.
34. Rosenberg, N., 1982, Inside the Black Box: Technology and Economics, New York: Cambridge University Press.
35. Scherer, F.M., 1990, Industrial Market Structure and Economic Performance, Boston: Houghton Mifflin.
36. _, 2000, "The Pharmaceutical Industry," in A.J. Culyer and J.P. Newhouse, eds., Handbook of Health Economics, 1B, New York: North-Holland, 1297-1336.
37. Schmalensee, R., 1972, The Economics of Advertising, New York: North-Holland.
38. Shaked, A. and J. Sutton, 1982, "Relaxing Price Competition through Product Differentiation," Review of Economic Studies, 49, 3-13.
39. Stern, S. and M. Trajtenberg, 1998, "Empirical Implications of Physician Authority in Pharmaceutical Decision-Making," NBER Working Paper No. 6851.
40. Suslow, V.Y., 1996, "Measuring Quality Change in the Market for Anti-Ulcer Drugs," in R.B. Helms, ed., Competitive Strategies in the Pharmaceutical Industry, Washington: The AEI Press, 49-72.
41. _, 1997, "Comment," in T.F. Bresnahan and R.J. Gordon, eds., The Economics of New Goods, 58, NBER Studies in Income and Wealth, Chicago: University of Chicago Press, 322-328.
42. Trajtenberg, M., 1990, "A Penny for Your Quotes: Patent Citations and the Value of Innovations," RAND Journal of Economics, 21, 172-187.
43. Wade, V.A., P.R. Mansfield, and P.J. McDonald, 1989, "Drug Companies' Evidence to Justify Advertising," The Lancet, 2, 1261-1264.
44. Werth, B., 1994, The Billion-Dollar Molecule, New York: Simon & Schuster.
45. Winslow, R., 2000, "Birth of a Blockbuster: Lipitor'S Unlikely Route Out of the Lab," The Wall Street Journal, January 24, B1.